The National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) has a long history of sponsoring clinical studies of new therapies. This application proposes new designs and statistical methods for NIDDK clinical studies. The primary emphasis of this application is the development of new designs for clinical trials and for dose-response studies which will better benefit the individual participant in the study. These new designs are response-driven; that is, responses from previous subjects in the study are used to ensure a higher probability that future subjects will be assigned to treatments or dose levels """"""""performing"""""""" better thus far. Response-driven designs have a rich history in biostatistical research and are attractive to clinicians, but are not utilized very often due to limitations of existing statistical techniques. A large part of this application addresses remedies which will make response-driven designs feasible for more Phase I-III clinical trials of new therapies for diseases of interest to the NIDDK. Little previous methodological work has addressed the use of response- driven designs for dose-response or toxicity studies. This project presents a randomized class of designs based on the generalized Polya urn model which allows targeting of a particular quantile and description of the dose- responsive relationship while protecting patients from being assigned to highly toxic dose levels. This class of designs is essentially nonparametric and allows a wide variety of design choices. Such designs will be of interest for pre-testing stages of new therapies for the obvious ethical benefits, but are also applicable to combined efficacy/toxicity responses, often of interest in Phase II trials. Problems with estimation and inference and issues in the practical implementation of the design are examined. Comparison with other existing methodology is proposed. Other response-driven designs are proposed, including a fully sequential design for dose-response studies, a design for titration or dose ranging experiments, a design appropriate for Phase III clinical trials with multiple treatment arms, and a design appropriate for survival trials. Each of these designs is motivated by realistic study scenarios, and ethical benefits are weighed along with issues of practical implementation; potential criticisms are addressed, and efforts made to propose solutions. Most NIDDK trials employ group sequential monitoring techiques. Two other topics, a monograph on group sequential monitoring of data in clinical trials, and a design for sequential monitoring of three treatment arms in a clinical trial when a standard randomization design is used, are also developed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
3R29DK051017-05S1
Application #
6141942
Study Section
Special Emphasis Panel (ZRG7 (17))
Program Officer
Jones, Camille A
Project Start
1999-09-01
Project End
2001-05-31
Budget Start
1999-09-01
Budget End
2001-05-31
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Maryland Balt CO Campus
Department
Biostatistics & Other Math Sci
Type
Schools of Arts and Sciences
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21250
Stallard, Nigel; Rosenberger, William F (2002) Exact group-sequential designs for clinical trials with randomized play-the-winner allocation. Stat Med 21:467-80
Rosenberger, W F; Stallard, N; Ivanova, A et al. (2001) Optimal adaptive designs for binary response trials. Biometrics 57:909-13
Ivanova, A; Rosenberger, W F (2000) A comparison of urn designs for randomized clinical trials of K > 2 treatments. J Biopharm Stat 10:93-107
Hu, F; Rosenberger, W F (2000) Analysis of time trends in adaptive designs with application to a neurophysiology experiment. Stat Med 19:2067-75
Palmer, C R; Rosenberger, W F (1999) Ethics and practice: alternative designs for phase III randomized clinical trials. Control Clin Trials 20:172-86
Coad, D S; Rosenberger, W F (1999) A comparison of the randomized play-the-winner rule and the triangular test for clinical trials with binary responses. Stat Med 18:761-9
Rosenberger, W F; Hu, F (1999) Bootstrap methods for adaptive designs. Stat Med 18:1757-67
Rosenberger, W F; Seshaiyer, P (1997) Adaptive survival trials. J Biopharm Stat 7:617-24
Durham, S D; Flournoy, N; Rosenberger, W F (1997) A random walk rule for phase I clinical trials. Biometrics 53:745-60